Dedrocorydaline (13-Metlpalmatine) droxyl is an alkaloid that regulates protein expression of p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dedrocorydaline droxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.
Dedrocorydaline droxy (0-200 μM) 处理以剂量依赖性方式显着抑制 MCF-7 细胞的生长。200 μM Dedrocorydaline droxyl 处理 24 小时后，细胞活力降低了约 40%[1]。
Dedrocorydaline droxyl (0-200 μM) 剂量依赖性地增加 Bax 蛋白表达并降低 Bcl-2 蛋白表达[1]。
Dedrocorydaline droxyl (0-200 μM) 诱导 caspase-7,-8 的激活和 PARP 的裂解而不影响 caspase-9[1]。
Dedrocorydaline droxy 表现出低急性毒性，小鼠口服的 LD50 约为 277.5±19.0 mg/kg 体重，腹腔注射为 21.1±1.4 mg/kg[4]。
[1]. Xu Z, et al. Dedrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85.
[2]. Yoo M, et al. Dedrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36.
[3]. Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244.
[4]. Yin ZY, et al. Antinociceptive effects of dedrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129.